Amylyx Pharmaceuticals, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Financial statements are unaudited. Amylyx is a clinical-stage biotechnology company developing AMX0035, primarily for ALS; it had no product-sales revenue.
Financial results and position
- Revenue and margins: No product revenue was reported; the filing provides no clear revenue figure for the quarter. Gross profit and operating margins are not meaningful for this pre-commercial company.
- Operating expenses: $47.8 million, up 272% from $12.9 million in Q1 2021. Research and development was $21.5 million (up 213%); general and administrative was $26.4 million (up 339%).
- Loss: Net loss was $47.8 million, versus $14.5 million in Q1 2021. Basic and diluted loss per share was $0.93, compared with $2.33; the much larger weighted-average share count reflects the IPO and conversion of preferred stock.
- Cash flow: Operating activities used $40.6 million, versus $12.6 million a year earlier. Investing activities used $99.3 million, largely reflecting purchases of short-term investments; financing provided $200.5 million, primarily from the IPO. Cash, cash equivalents and restricted cash ended at $110.8 million.
- Liquidity: Cash and cash equivalents were $110.4 million and short-term investments were $144.8 million, totaling $255.2 million in available cash and investments. Current assets were $265.5 million and current liabilities $27.7 million.
- Debt and other obligations: No convertible notes or other borrowings were outstanding at quarter-end. Operating lease liabilities totaled $7.2 million; undiscounted future lease payments were $8.2 million. Accumulated deficit was $203.7 million.
Material changes versus Q1 2021
- R&D costs rose mainly with the Phase 3 PHOENIX ALS trial, manufacturing development and commercialization preparation; G&A increased with hiring, professional services and commercial-readiness work.
- January 2022 IPO generated approximately $196.4 million in net proceeds. All preferred shares converted into common stock. At March 31, 2022, 57.9 million common shares were outstanding.
- Cash and short-term investments increased substantially following the IPO. Operating cash use also increased as the company expanded development and launch-preparation activities.
- Adoption of lease accounting standard ASC 842 in January added right-of-use assets and lease liabilities; it did not materially affect operations.
Outlook, commentary and risks
- The FDA’s target action date for the AMX0035 ALS application was June 29, 2022. At the March 30 advisory committee meeting, the vote on whether the CENTAUR trial and its open-label extension established effectiveness was 4 in favor and 6 opposed. The committee recommendation was non-binding, and FDA approval remained uncertain; the filing said further clinical data might be required.
- The global Phase 3 PHOENIX trial was ongoing, with U.S. enrollment complete and European enrollment continuing. Amylyx anticipated topline results in 2024. The company also reported an FDA-authorized U.S. expanded-access program launched in March.
- Applications for AMX0035 had been submitted in Canada and the United States; the European application was validated in Q1. The company was preparing for potential commercialization but gave no sales or earnings guidance.
- Management expected operating losses and cash outflows to continue and forecast that March 31 cash, cash equivalents and investments would fund operations and capital needs for at least 12 months after the filing date. This estimate depends on assumptions and could prove wrong; additional funding may be needed.
- Key risks include regulatory and clinical uncertainty, trial enrollment or timing delays, manufacturing and supply constraints, competition, commercialization and reimbursement challenges, and COVID-19-related disruption. Grant agreements also include contingent future royalties or payments tied to commercialization or revenue-generating transactions; amounts were not accrued because achievement and timing were not considered probable or estimable.
- No material legal proceedings or material subsequent events were reported. Management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- FDA’s decision on AMX0035, including whether further clinical evidence is required after the advisory committee vote.
- PHOENIX enrollment, trial execution and expected 2024 topline-results timing.
- Actual cash burn and runway relative to management’s estimate, including commercial-launch and manufacturing spending.
- Potential dilution from equity awards and future financing; 8.99 million options and 596,709 unvested restricted stock units were outstanding at quarter-end.
- Potential future grant-related royalty obligations if products are commercialized or related revenue-generating transactions occur.